Novartis
NEWS
CryoPort handles the products for more than 172 of the more than 800 immunotherapy trials underway.
Days after plunking down $3.9B+ for AAA, Novartis may be looking to divest itself of its generic dermatology drug business.
Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9B acquisition of Advanced Accelerator Applications.
Big pharmas are having a good year so far in terms of FDA approvals.
The FDA based its decision on data from the COMBI-AD Phase III trial.
A look at how the gene therapy approvals may end up confusing payers, lawmakers, and the general public at a time when the industry desperately needs clarity.
The long term study results were published online in Blood.
Novartis is closing its generic-drug manufacturing facility in Broomfield, Colo., which will cut 450 jobs over two years.
JOBS
IN THE PRESS